All updates
All updates
today 212中文产业新闻Chinese source评分7070 中文产业新闻Chinese source评分6060 FDA 受理首个帕博利珠单抗生物类似药 FYB20 上市申请
中文产业新闻Chinese source评分6161 卞修武院士团队在 Cancer Cell 报道 FOSL2 介导酸化驱动胃癌免疫耐药机制
中文产业新闻Chinese source评分7171 信达生物 IBI311 三期 RESTORE-3 达主要终点，突眼应答率 60.4%
中文产业新闻Chinese source评分6868 罗氏获大睿生物ALK7靶向RNAi候选物全球独家许可，总额近12亿美元
中文产业新闻Chinese source评分5959 axatilimab 特发性肺纤维化二期试验未达主要终点
中文产业新闻Chinese source评分2828 NEJM长篇综述：乳腺癌全身治疗的进展
中文产业新闻Chinese source评分7272 恒瑞HRS-1596以26亿美元海外授权诺和诺德，改写GLP-1赛道竞争逻辑
中文产业新闻精选Chinese source评分7171 罗氏1亿美元首付获大睿生物ALK7肥胖症项目权益，总额最高11.6亿美元
中文产业新闻Chinese source评分4444 强生2026Q3：传奇CAR-T增长47%，IL-23单抗增长70%，双抗增长61%
中文产业新闻Chinese source评分6464 厦门大学王耿团队在Cell Research揭示镁离子经RNASET2激活抗肿瘤免疫
中文产业新闻Chinese source评分6868 麻省理工在 Science 发表研究，揭示神经酰胺-YAP1 通路驱动结直肠癌肝转移
中文产业新闻Chinese source评分6262 未做III期临床的K药生物类似药FYB206获FDA受理
中文产业新闻Chinese source评分6363 大睿生物与罗氏达成 ALK7 RNAi 全球独家许可合作，最高 11.6 亿美元
中文产业新闻Chinese source评分5050 axatilimab 治疗 IPF 的 MAXPIRe II 期未达主要终点，Syndax 股价盘后大跌近 17%
中文产业新闻Chinese source评分5858 辉瑞与Enodia达成超5亿美元合作 开发Sec61靶向小分子降解剂
中文产业新闻精选Chinese source评分8989 康方依沃西一线晚期肺癌头对头 K 药 总生存期 30.8 个月对 22.6 个月
中文产业新闻精选Chinese source评分7272 BioNTech BNT113联合帕博利珠单抗AHEAD-MERIT 2/3期首批顶线未达PFS主要终点
中文产业新闻Chinese source评分6868 BioNTech BNT113 mRNA肿瘤疫苗AHEAD-MERIT研究未达PFS主要终点
中文产业新闻Chinese source评分7373 董民团队在Cell报道介导破伤风毒素入侵中枢神经系统的宿主受体PTPRS
临床试验登记评分2222 A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
临床试验登记评分3434 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
临床试验登记评分2525 Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1
临床试验登记评分3232 Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
临床试验登记评分3535 Vortosiran in Atrial Fibrillation
临床试验登记评分2424 ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
临床试验登记评分3232 Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
临床试验登记评分2929 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
临床试验登记评分1818 ITR-251 in Patients With Advanced Solid Tumors
临床试验登记评分2929 Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
临床试验登记评分3535 BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
临床试验登记评分3030 Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
STAT News评分4343 STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds
STAT News评分4040 Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69
Nature评分2121 Author Correction: Parkinson’s disease as a somato-cognitive action network disorder
FDA Drugs评分4343 BsUFA II: Fiscal Years 2018 - 2022
BioPharma Dive评分6868 BioNTech mRNA cancer immunotherapy misses first objective in key study
中文产业新闻Chinese source评分4040 强生上调2026年业绩指引，Q3 CD38销售额42亿美元、CAR-T 7.1亿、A+L 3.2亿
中文产业新闻Chinese source评分6262 BioNTech BNT113 联合帕博利珠单抗头颈癌 2/3 期试验未达 PFS 主要终点
中文产业新闻Chinese source评分6161 BMS LPA1 拮抗剂 IPF 三期：60mg 达主要终点，120mg 未达标